INHIBIKASE THERAPEUTICS INC (IKT) Stock Income Statement
NASDAQ:IKT - Nasdaq - US45719W2052 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 260.50K | 120.00K | 3.10M | |||
| Operating Expenses | 38.40M | 28.59M | 20.35M | 18.25M | 17.87M | |||
| Research and Development | 24.97M | 17.21M | 13.62M | 12.03M | 11.36M | |||
| Selling, General, and Administrative Expenses | 14.60M | 11.38M | 6.73M | 6.22M | 6.51M | |||
| Operating Income | -38.40M | -28.59M | -20.09M | -18.13M | -14.77M | |||
| Interest Income/Expense | 1.86M | 1.07M | 1.06M | 70.00K | -20.00K | |||
| Income Before Taxes | -36.55M | -27.52M | -19.03M | -18.05M | -14.79M | |||
| Net Income | -36.55M | -27.52M | -19.03M | -18.05M | -14.79M | |||
| EBITDA | -38.37M | -28.56M | -19.91M | -18.12M | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.21 | -1.16 | -3.57 | -4.30 | -3.53 | |||
| Non GAAP EPS | -1.98 | -2.54 | -3.57 | -4.32 | N/A | |||
| Statistics | ||||||||
| Profit Margin | N/A | N/A | -7304.76% | -15041.67% | -477.10% | |||
| Operating Profit Margin | N/A | N/A | -7712.02% | -15108.33% | -476.45% | |||
All data in USD